Navigation Links
InterMune Reports First Quarter 2011 Financial Results and Business Highlights
Date:4/28/2011

ime line.
  • InterMune has a number of granted, allowed and pending patent applications in Europe relating to Esbriet's formulation and use in IPF patients.  InterMune reported that three such patents have now been granted by the European patent office.  The first relates to the effect of food on the pharmacokinetics and safety of pirfenidone in IPF patients and expires in late 2026.  A second relates to the safe usage of Esbriet in patients who develop elevation in liver transaminase levels, which expires in late 2029, and a third relates to the titration of the dosing of Esbriet at the initiation of therapy, which expires in late 2027.  In addition, the company has two other patents that have been allowed, one which relates to the contraindicated use of pirfenidone in combination with fluvoxamine, and the second which relates to discontinuing smoking in connection with the use of pirfenidone. Both of these patents expire in 2030. Several other patents are still under review in Europe.
  • InterMune announced that it launched in April a program that allows qualified physicians to make Esbriet available to their IPF patients, if they meet certain pre-specified medical criteria and conditions, free of charge before Esbriet is commercially available throughout Europe.  The program is a so-called Named Patient Access Program (NPP) and has begun enrolling patients.  The NPP is focused on the major countries of Europe and is expected to continue for approximately 12 months.
  • InterMune today reported that pirfenidone will be the subject of an oral presentation and a poster discussion at the International Conference of the American Thoracic Society (ATS), May 13-18 in Denver, Colo.:
  • C93 Oral Presentation: The Effect of Treatment with Pirfenidone on Longitudinal Change in Lung Volume in Patients with Idiopathic Pulmonary Fibrosis (IPF): A Meta-Analysis of Outcomes in Four Randomized Controlled Clinical Trials
  • Autho
    '/>"/>

  • SOURCE InterMune, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. InterMune to Present at Canaccord Adams Conference
    2. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
    3. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
    4. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
    5. InterMune to Release Third Quarter 2008 Financial Results on November 6
    6. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
    7. InterMune to Present at Deutsche Bank Biotech Boston Confab
    8. InterMune to Present at J.P. Morgan Healthcare Conference
    9. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
    10. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
    11. InterMune Announces Issuance of U.S. Patent for ITMN-191
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/15/2014)... Hydro Dynamics, Inc. (HDI) of Rome, ... will be partnering with Proteaf Technologies (Proteaf) of ... implementing its Shock Wave Power Reactor (SPR) cavitation ... flow chemistry through process intensification has been widely ... for decades. The continuous chemistry has been ...
    (Date:9/13/2014)... PA (PRWEB) September 13, 2014 Boehringer ... device innovations, is proud to announce the successful broadcast ... Network bariatric surgeons Leonardo Claros, MD, FACS, FAMBS, and ... 3Dâ„¢ Sleeve Gastrectomy Calibration System. , This sleeve ... postgraduate course of more than four hundred surgeons from ...
    (Date:9/12/2014)... 12, 2014 Research and Markets ... Film Photoresist Industry Report 2014" report to their ... Industry Report 2014 is a professional and in-depth study ... photoresist industry . The report provides a ... and industry chain structure. The dry film photoresist market ...
    (Date:9/11/2014)... MD (PRWEB) September 12, 2014 ... (LIMS), radio-frequency identification (RFID) solutions and sample management ... 5.1. , RURO completed work on the most ... August and it has already seen mass adoption, ... major release of version 5.0 brought an entirely ...
    Breaking Biology Technology:Hydro Dynamics Partners with the Continuous Flow Chemistry Experts of Proteaf Technologies 2Boehringer Laboratories, Inc. Announces Live Surgery Using Innovative System to Calibrate Sleeve Gastrectomy 2Global Dry Film Photoresist Industry Report 2014 2Limfinity® Version 5.1 Available 2
    ... , DURHAM, N.C., Aug. 12 Oxygen Biotherapeutics, Inc. (OTC Bulletin ... 10-K for the fiscal year ended April 30, 2009. In addition to being available ... v , the 10-K can be downloaded from the company website at ... the Investors page. , , For the year ended April 30, ...
    ... , , LYNBROOK, N.Y., Aug. 12 ... company developing first in class collagenase-based products, today announced its ... , , "We were very pleased ... with Priority Review for XIAFLEX(TM) for the treatment of Dupuytren,s ...
    ... , , SAN DIEGO, Aug. 12 ... results for the three and six months ended June 30, 2009. , ... have the capital to complete and submit a New Drug Application (NDA) ... said Brian M. Culley, Principal Executive Officer at ADVENTRX. "Our financial ...
    Cached Biology Technology:Oxygen Biotherapeutics, Inc. Files 10-K for Fiscal Year Ended April 30, 2009 2Oxygen Biotherapeutics, Inc. Files 10-K for Fiscal Year Ended April 30, 2009 3BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 2BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 3BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 4BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 5BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results 6ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 2ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 3ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 4ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 5ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 6ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results 7
    (Date:9/15/2014)... week,s print issue of the journal Science ... New Mexico, Montana and even the Netherlands, thanks to ... more the norm in these connected times. Yes, the ... produce innovations in biology, medicine, biotechnology and agriculture. It ... talked with that one, that one knew another one, ...
    (Date:9/15/2014)... leading coral reef ecologists fears that reef biodiversity may ... that we once thought. , In an international study ... of Excellence for Coral Reef Studies (Coral CoE) says ... species within reef ecosystems. , In coral reefs, just ... that keep the ecosystem safe and functioning. , ...
    (Date:9/15/2014)... new strategic vision document, released today by the ... the long-term goals, objectives, and strategies for the ... over the next five years (2015-2020). In ... activities, to be funded in 2015, will include ... fellowships. , The $500 million, 30-year program ...
    Breaking Biology News(10 mins):Collaboration drives achievement in protein structure research 2Specialized species critical for reefs 2NAS Gulf Research Program announces strategic vision, initial opportunities 2NAS Gulf Research Program announces strategic vision, initial opportunities 3NAS Gulf Research Program announces strategic vision, initial opportunities 4
    ... , , , , , , , ... , , , ... file available on request).,This noisy frog is a potent... , Click here for more ... , , , , , , ...
    ... with obese children shows that all diets are effective in ... one that accounts for how many carbs are in the ... glucose levels may be most promising. The Cincinnati ... and portion-controlled diets with obese children is published online in ...
    ... team has identified epigenetic signatures, markers on DNA that ... cells. These signatures can predict the expression of a ... stem cells (iPSCs), cells that take on embryonic stem ... is controlled brings us one step closer to developing ...
    Cached Biology News:Common North American frog identified as carrier of deadly amphibian disease 2Common North American frog identified as carrier of deadly amphibian disease 3Common North American frog identified as carrier of deadly amphibian disease 4New study compares diets for weight management in obese children 2Epigenetic signatures direct the repair potential of reprogrammed cells 2
    Identify and characterize Phosphoinositide (PI(3,4,5)P3) binding...
    Mouse monoclonal antibody to RNase L...
    Compact, portable device, seals 96 and 384 well plates with preset temperature optimised for Eppendorf heat sealing foils and films. Suitable for plates of different heights. AC input: 50/60 Hz230 V...
    ... Caliper is proud to work in ... Automation Certified 25mm syringe filters in a ... filters are licensed for use on the ... Detailed Specifications and Pricing for our Automation ...
    Biology Products: